Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guerin (BCG) immunotherapy

Simple item page
dc.contributor.authorBaştürk, Bilkay
dc.contributor.buuauthorYavaşoğlu, İsmet
dc.contributor.buuauthorOral, Barboros
dc.contributor.buuauthorGöral, Güher
dc.contributor.buuauthorOktay, B.
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Üroloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Mikrobiyoloji ve Enfeksiyon Hastalıkları Anabilim Dalı/İmmünoloji Birimi.tr_TR
dc.contributor.orcid0000-0003-0463-6818tr_TR
dc.contributor.researcheridK-7285-2012tr_TR
dc.date.accessioned2021-09-13T13:23:00Z
dc.date.available2021-09-13T13:23:00Z
dc.date.issued2006
dc.description.abstractVarious types of cancer are more frequent in men than women, and bladder cancer is one of the most common of these. Intravesical instillation of Bacillus Calmette-Guerin (BCG) after transurethral resection is the most effective treatment for superficial bladder cancers. The main aim of this study was to investigate for possible links between cytokine gene polymorphisms and different outcomes after BCG immunotherapy. Sixty patients who had been diagnosed with transitional cell cancer were investigated. All genotyping experiments were performed using polymerase chain reaction sequence-specific primers and a commercially available kit. The genes investigated were those that code for interleukin (IL)-1 alpha, IL-1 beta, IL-1R, IL-1RA, IL-4RA, IL-2, IL-4, IL-6, IL-10, IL-12, interferon-7 (IFN-7), transforming growth factor-beta (TGF-beta), and tumor necrosis factor-alpha (TNF-alpha). Analyses of the data identified TGF-beta codon 25 GG (92.85% vs. 64.44%, p = 0.04, OR = 7.17), IL-4-1098 GG (16.6% vs. 0.0%, p = 0.05, OR = 18.33), 1L-10-1082 GG (28.5% vs. 6.8%, p = 0.05, OR = 5.47), and IL-10-1082 GCC/GCC (28.57% vs. 4.5%, p = 0.025, OR = 8.4) polymorphisms as risk factors for progression of bladder cancer.en_US
dc.identifier.citationBaştürk, B. vd. (2006). ''Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guerin (BCG) immunotherapy''. Cytokine, 35(1-2), 1-5.en_US
dc.identifier.endpage5tr_TR
dc.identifier.issn1043-4666
dc.identifier.issn1096-0023
dc.identifier.issue1-2tr_TR
dc.identifier.pubmed16938461tr_TR
dc.identifier.scopus2-s2.0-33749239193tr_TR
dc.identifier.startpage1tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.cyto.2006.06.009
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1043466606001931
dc.identifier.urihttp://hdl.handle.net/11452/21915
dc.identifier.volume35tr_TR
dc.identifier.wos000241494600001tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevier Scienceen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalCytokineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmunologyen_US
dc.subjectCell biologyen_US
dc.subjectBiochemistry & molecular biologyen_US
dc.subjectBladder tumoren_US
dc.subjectTransforming growth factoren_US
dc.subjectPolymorphismInterleukin-10en_US
dc.subjectCytokineen_US
dc.subjectImmunotheraphyen_US
dc.subjectBCGen_US
dc.subjectTgf-beta-1en_US
dc.subjectExpressionen_US
dc.subjectTranscriptionen_US
dc.subjectTnf-alphaen_US
dc.subjectGrowth-factor-betaen_US
dc.subjectCell carcinomaen_US
dc.subjectInterleukin-10 geneen_US
dc.subjectIfn-gammaen_US
dc.subjectBladder-canceren_US
dc.subjectIn-vitroen_US
dc.subject.scopusMycobacteria Bovi BCG; Urinary Bladder Neoplasms; Intravesical Drug Administrationen_US
dc.subject.wosImmunologyen_US
dc.subject.wosCell biologyen_US
dc.subject.wosBiochemistry & molecular biologyen_US
dc.titleCytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guerin (BCG) immunotherapyen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus